Clinical Study

A Phase III Study Of Postoperative Radiation Therapy (Imrt) +/- Cetuximab For Locally-Advanced Resected Head And Neck Cancer

Posted Date: Feb 12, 2014

  • Investigator: Kevin Redmond
  • Co-Investigator: Michelle Adams
  • Specialties: Hematology/Oncology, Oncology, Surgery, Otolaryngology, Radiation Oncology, Surgical Oncology, Head & Neck Cancer, Cancer
  • Type of Study: Drug

This study will compare the good and bad effects of radiation therapy alone with radiation therapy and cetuximab to find out which is better. Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. Follow-up visits will continue indefinitely. Approximately 700 people will participate in this study with 5 participating locally.


Eligible Patients Must Have Head And Neck Cancer That After Surgery Has An Intermediate Risk Of Recurring


Head And Neck Cancer, R0920, Recurrent, Resected, Null

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.